Give Cas a Chance: An Actionable Path to a Platform for CRISPR Cures
By Fyodor Urnov,
The CRIPSR Journal
| 10. 18. 2024
The field of clinical gene editing has a bona fide crisis on its hands—a crisis that has to, and can be, promptly resolved.
An outside observer of our field might be surprised by this and say—what crisis? The first gene-editing medicine, Casgevy,1 was approved less than 12 months ago. The clinical trial efficacy and safety data supporting this approval are spectacular.2,3Significantly, Casgevy is indicated for the two most common Mendelian disorders on Earth, sickle cell disease and transfusion-dependent β-thalassemia. At the same time, gene editing has advanced to two phase 3 clinical trials, one of which, for transthyretin (TTR) amyloidosis, is enrolling 765 subjects;4 this is based on equally spectacular phase 1/2 data for safety, tolerability, and durability of effect on an efficacy biomarker.5 Further, results of a PubMed search for “CRISPR or Cas9” resemble the Amazon rainforest with its rich ecosystem of publications describing not only nonclinical data of efficacy for gene-editing treatment of various diseases, but discoveries of new enzymes to drive gene editing, new methods to derisk them, and...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
Alice Wong, founder of the Disability Visibility Project, MacArthur Genius, liberationist, storyteller, writer, and friend of CGS, died on November 14. Alice shone a bright light on pervasive ableism in our society. She articulated how people with disabilities are limited not by an inability to do things but by systemic segregation and discrimination, the de-prioritization of accessibility, and the devaluation of their lives.
We at CGS learned so much from Alice about disability justice, which goes beyond rights...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
